Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vs Intravenous Pembrolizumab in First-line Metastatic NSCLC
NCT06698042Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of berahyaluronidase alfa + pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Nov 2024; status: active, not recruiting.
02
Drugs
berahyaluronidase alfa + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06698042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698042.